EIP logo

Copyright © 2007-2024 European Immunogenicity Platform

Location photo

2nd Open Scientific EIP Symposium Immunogenicity of Biopharmaceuticals

17th — 19th November 2009

Leiden, the Netherlands


Proposed Mechanisms for Aggregate Induced Immunogenicity
Bachmann (Cytos biotechnology)
The Effects of Induced Aggregation of IgG and Insulin Preparations on In Vitro T Cell Stimulation
Baker (Antitope)
Large-scale T cell Epitope Discovery tools
Soren Buus (University of Copenhagen)
Screening & Confirmatory Cut-Points - Brief Overview & Answers to some FAQs
V. Devanarayan (Abbott Laboratories, USA)
Correlation of ADA with Clinical and Non-Clinical Study Endpoints: A Case Study and Lessons Learned
Deborah Finco (Pfizer, USA)
Heparin-induced Thrombocytopenia the most frequent drug induced immune response
Andreas Greinacher (Universität Greifswald, Germany)
Selective removal of B cell epitopes from bacterial proteins: Exemplified by the generation of a novel C5a receptor antagonist for treatment of acute inflammation
Erika Gustafsson (Alligator Bioscience)
Workshop presentation: Development and application of Bioinformatics methods
Ole Lund
Prediction of immunogenicity of peptide drugs using bioinformatics
Ole Lund
A role for complement and immune complexes in immune responses to therapeutic antibodies?
Claus H. Nielsen (Copenhagen University Hospital, Denmark)
Immunogenicity of recombinant human therapeutics characterization of the underlying immune response
Melody Sauerborn (Universiteit Utrecht)
Recommendations for immunoassay methods used for the detection of host antibodies against biotechnology products
Gopi Shankar (Centocor, USA)
Structural Aspects of Immunogenicity: Aggregates
Ronald Smulders (Schering-Plough)
Immunogenicity of biotherapeutics
Stas (Algonomics)
Quantification of Neutralizing Antibodies to Biopharmaceuticals using a Novel Cell-Bassed Assay Platform Technology
Michael G Tovey (Institut André Lwoff, France)
Antibodies and immunological memory induced by aggregated interferon beta in a transgenic immune tolerant mouse model
Miranda van Beers (UIPS Utrecht Institute for Pharmaceutical Sciences)
Immunogenicity of therapeutic antibodies Clinical Significance
Gertjan Wolbink (Jan van Breemen Instituut)
Wrap-Up and Look Forward
Steven J Swanson (AMGEN)
Back to top